PHASE 1B STUDY OF THE SRC INHIBITOR DASATINIB WITH FOLFOX AND CETUXIMAB IN REFRACTORY METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Kopetz, S. [1 ]
Wolff, R. [1 ]
Eng, C. [1 ]
Overman, M. [1 ]
Henry, L. [1 ]
Coulson, R. [1 ]
Garrett, C. [1 ]
Abbruzzese, J. [1 ]
Gallick, G. [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [21] Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC)
    Bendell, J.
    Won, K. Tae
    Ean, C. Cheng
    Yung-Jue, B.
    Lee, C.
    Desai, J.
    Lewin, J.
    Wallin, J.
    Das Thakur, M.
    Mwawasi, G.
    Cha, E.
    Infante, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 140 - 140
  • [22] Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI plus /-evacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)
    Bendell, J.
    Hubbard, J.
    O'Neil, B. H.
    Jonker, D.
    Starodub, A.
    Peyton, J.
    Pitot, H.
    Halfdanarson, T.
    Nadeau, B.
    Zubkus, J.
    Adesunloye, B.
    Edenfield, J.
    Li, Y. Z.
    Li, W.
    Grothey, A.
    Borodyansky, L.
    Li, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells
    Lori Rice
    Sharon Lepler
    Christina Pampo
    Dietmar W. Siemann
    Clinical & Experimental Metastasis, 2012, 29 : 133 - 142
  • [24] FOLFOX4 With Cetuximab vs. UFOX With Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: The Randomized Phase II FUTURE Study
    Douillard, Jean-Yves
    Zemelka, Tomasz
    Fountzilas, George
    Barone, Carlo
    Schlichting, Michael
    Heighway, Jim
    Eggleton, S. Peter
    Srimuninnimit, Vichien
    CLINICAL COLORECTAL CANCER, 2014, 13 (01) : 14 - U39
  • [25] Cetuximab plus FOLFIRI for irinotecan-refractory metastatic colorectal cancer: A retrospective study
    Koo, Dong Hoe
    Lee, Jae-Lyun
    Kim, Tae Won
    Ryu, Min-Hee
    Chang, Heung Moon
    Lee, Sung Sook
    Kim, Min Kyoung
    Sym, Sun Jin
    Lee, Jung Shin
    Kang, Yoon-Koo
    ANNALS OF ONCOLOGY, 2006, 17 : 131 - 131
  • [26] Safety and Efficacy of FOLFOX Followed by Cetuximab for Metastatic Colorectal Cancer With Severe Liver Dysfunction
    Elsoueidi, Raymond
    Craig, Jessica
    Mourad, Hesham
    Richa, Elie M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (02): : 155 - 160
  • [27] Divarasib plus cetuximab in KRASG12C-positive colorectal cancer: a phase 1b trial
    Desai, Jayesh
    Alonso, Guzman
    Kim, Se Hyun
    Cervantes, Andres
    Karasic, Thomas
    Medina, Laura
    Shacham-Shmueli, Einat
    Cosman, Rasha
    Falcon, Alejandro
    Gore, Eelke
    Guren, Tormod
    Massarelli, Erminia
    Miller, Wilson H., Jr.
    Paz-Ares, Luis
    Prenen, Hans
    Amatu, Alessio
    Cremolini, Chiara
    Kim, Tae Won
    Moreno, Victor
    Ou, Sai-Hong, I
    Passardi, Alessandro
    Sacher, Adrian
    Santoro, Armando
    Stec, Rafal
    Ulahannan, Susanna
    Arbour, Kathryn
    Lorusso, Patricia
    Luo, Jia
    Patel, Manish R.
    Choi, Yoonha
    Shi, Zhen
    Mandlekar, Sandhya
    Lin, Mark T.
    Royer-Joo, Stephanie
    Chang, Julie
    Jun, Tomi
    Dharia, Neekesh, V
    Schutzman, Jennifer L.
    Han, Sae-Won
    NATURE MEDICINE, 2024, 30 (01) : 271 - +
  • [28] Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
    Janja Ocvirk
    Thomas Brodowicz
    Fritz Wrba
    Tudor E Ciuleanu
    Galina Kurteva
    Semir Beslija
    Ivan Koza
    Zsuzsanna Pápai
    Diethelm Messinger
    Ugur Yilmaz
    Zsolt Faluhelyi
    Suayib Yalcin
    Demetris Papamichael
    Miklós Wenczl
    Zrinka Mrsic-Krmpotic
    Einat Shacham-Shmueli
    Damir Vrbanec
    Regina Esser
    Werner Scheithauer
    Christoph C Zie-linski
    World Journal of Gastroenterology, 2010, 16 (25) : 3133 - 3143
  • [29] Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
    Ocvirk, Janja
    Brodowicz, Thomas
    Wrba, Fritz
    Ciuleanu, Tudor E.
    Kurteva, Galina
    Beslija, Semir
    Koza, Ivan
    Zsuzsanna Papai
    Messinger, Diethelm
    Yilmaz, Ugur
    Zsolt Faluhelyi
    Yalcin, Suayib
    Papamichael, Demetris
    Miklos Wenczl
    Mrsic-Krmpotic, Zrinka
    Shacham-Shmueli, Einat
    Vrbanec, Damir
    Esser, Regina
    Scheithauer, Werner
    Zielinski, Christoph C.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (25) : 3133 - 3143
  • [30] Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC).
    Sawyer, M. B.
    Iqbal, S.
    Lenz, H.
    Lima, C. S. Rocha
    Rossignol, D. P.
    Krivelevich, I.
    Fan, J.
    El-Khoueiry, A. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345